Innovations in diagnosis and treatment of multiple sclerosis

Professor Joseph Berger proposes new ways of treating progressive multifocal leukoencephalopathy (PML) in MS

Dr. Berger has served as a consultant and/or on the PML adjudication committees of Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Eisai, EMD Serono, Genentech, Genzyme, Janssen, Merck, Millennium/Takeda, Novartis, Parexel, and Pfizer. He has received grants from Biogen. He also serves on the Scientific Advisory Boards of ExcisionBio, NeuVir and Inhibikase.